MedPath

A feasibility study to assess the safety and efficacy of JenaValve for patients with severe aortic regurgitation (AR).

Not Applicable
Suspended
Conditions
Aortic Regurgitation
Cardiovascular - Other cardiovascular diseases
Registration Number
ACTRN12616000718448
Lead Sponsor
JenaValve Technology, Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
All
Target Recruitment
15
Inclusion Criteria

1. Patient with severe aortic regurgitation (AR) assessed by echocardiography
2. Patient at high risk for open surgical valve replacement
3. Patient symptomatic according to NYHA functional class II or higher.

Exclusion Criteria

1. Congenital uni- or bicuspid aortic valve morphology
2. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
3. Endocarditis or other active infection
4. Need for urgent or emergent TAVR procedure for any reason
5. Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath